Loading stock data…
$16.23+0.14 (+0.87%)
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.
AVBP in the Healthcare sector is trading at $16.29 with a market capitalization of $803M. Wall Street consensus targets $20.56 (9 analysts), implying a +26.2% move over the next 12 months. The stock is currently 55% below its 52-week high of $35.83, remaining 40.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 18 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$52.69M↓ | -$46.11M↓ | -$38.82M↓ | -$38.32M↓ | -$33.62M |
| Net Income | -$49.89M↓ | -$43.32M↓ | -$35.54M↓ | -$34.98M↓ | -$31.40M |
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is fir...